Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 4Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Peritoneal Neoplasms 2Mesothelioma 1Malignant Solid Tumour 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × nintedanib × Clear all
NCT01024920 2021-07-19

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Boehringer Ingelheim

Phase 2 Completed
99 enrolled 45 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡